AI Efficiency And Engagement Based Pricing Will Shape Musculoskeletal Care Outlook

Catalysts

About Hinge Health

Hinge Health provides technology enabled care programs focused on musculoskeletal conditions, combining digital physical therapy, connected hardware and in person provider networks.

What are the underlying business or industry changes driving this perspective?

• Although the company is expanding its reach to roughly 25 million contracted lives and 783,000 members, future revenue growth still depends on converting a large pool of eligible lives in a market where employer benefit budgets and plan designs can limit further adoption, which may constrain billings and revenue.
• While AI driven care tools and the Robin assistant have supported an 85% gross margin and strong operating leverage, further efficiency gains could be harder to capture as the easiest workflow wins are already in place, which could slow future improvement in operating margin and earnings.
• Although HingeSelect is positioned around high quality providers and lower cost care, it is a multi year buildout of a two sided network. It is not expected to have material revenue impact until at least 2027, so near term profitability metrics may absorb investment without a matching uplift in revenue.
• Even with high client retention at 97% and head to head win rates at all time highs, large employers and health plans continually reassess vendors. Maintaining current net dollar retention above 110% may therefore require higher sales and account management spend, which could pressure net margins if contract economics do not improve.
• Although the move to engagement based pricing is aligned with client interests and current average selling price is essentially flat, the model ties revenue more tightly to actual member usage. This introduces a risk that any slowdown in engagement or enrollment yield from the current 3.9% level would weigh on revenue and earnings growth.

Assumptions

This narrative explores a more pessimistic perspective on Hinge Health compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Hinge Health's revenue will grow by 16.9% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -72.1% today to 13.3% in 3 years time.
• The bearish analysts expect earnings to reach $125.4 million (and earnings per share of $1.72) by about February 2029, up from $-424.1 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $173.5 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 41.3x on those 2029 earnings, up from -7.7x today. This future PE is greater than the current PE for the US Healthcare industry at 23.9x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Musculoskeletal care continues to be a major cost category in health care, and Hinge Health is currently serving roughly 24.6 million contracted lives out of an estimated 215 million people in its current markets. If employers and health plans keep adding digital MSK solutions and Hinge Health wins a larger share of that open opportunity, billings, revenue and earnings could rise faster than a flat share price view implies.
• The company reported strong unit economics, with 2025 revenue of US$588 million, a full year operating margin of 20% and a free cash flow margin of 31%. Management is guiding to higher revenue and operating income in 2026, so if these profitability and cash flow trends stay resilient, investors may be willing to pay more for that earnings and free cash flow profile over time.
• Hinge Health is already using AI tools and its Robin assistant to serve 47% more members while keeping care team costs flat and reports gross margins of 83% for 2025 and 85% in Q4 2025. Any further efficiency gains from technology and automation could support higher gross margins, stronger operating leverage and ultimately higher earnings than a stagnant share price outlook assumes.
• HingeSelect is still early, with limited expected revenue contribution until at least 2027, but it is building a two sided provider network that management believes can create a lasting moat. If this product scales successfully on top of the existing digital physical therapy base, it could open up new revenue streams, support higher net margins and change how the market values the company.
• The company is already working with more than 60 health plans and ecosystem partners, reports client retention of 97% and net dollar retention above 110%, and is expanding into fully insured, Medicare Advantage and federal programs. If these relationships continue to deepen and new channels like the Medicare ACCESS program add volume, recurring revenue and earnings could grow faster than a flat share price view reflects.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Hinge Health is $43.4, which represents up to two standard deviations below the consensus price target of $57.94. This valuation is based on what can be assumed as the expectations of Hinge Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $72.0, and the most bearish reporting a price target of just $43.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $939.3 million, earnings will come to $125.4 million, and it would be trading on a PE ratio of 41.3x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $41.31, the analyst price target of $43.4 is 4.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.